Antileukemia T-cell responses in CLL - We don't need no aberration

Oncoimmunology. 2015 Mar 16;4(7):e1011527. doi: 10.1080/2162402X.2015.1011527. eCollection 2015 Jul.


Effective antigen-specific cancer immunotherapy requires exact knowledge of tumor-associated epitopes that can act as rejection antigens. Although the current paradigm views mutation-derived neoantigens as the most promising targets, we have recently demonstrated that leukemia-specific T-cell responses associated with survival benefit in CLL patients target a panel of non-mutated tumor-associated antigens.

Keywords: cancer immunotherapy; chronic lymphocytic leukemia; neoantigen; tumor-associated antigen.